

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Tofacitinib for treating ankylosing spondylitis ID3865

Provisional stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Pfizer (tofacitinib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Arthritis Action • Arthritis and Musculoskeletal Alliance • Back Care • National Ankylosing Spondylitis Society • Pain Concern • Pain Relief Foundation • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance • Versus Arthritis <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Geriatrics Society • British Institute of Musculoskeletal Medicine • British Orthopaedic Association • British Pain Society • British Society for Paediatric and Adolescent Rheumatology • British Society of Rehabilitation Medicine • Chartered Society for Physiotherapy • Royal College of Occupational Therapists • Physiotherapy Pain Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Society of Medicine • UK Clinical Pharmacy Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Abbvie (adalimumab) • Amgen (adalimumab) • Biogen Biosimilars (adalimumab, etanercept, infliximab) • Celltrion Healthcare (infliximab) • Frensius Kabi (adalimumab) • Merck Sharpe and Dohme (golimumab, infliximab) • Novartis (secukinumab) • Pfizer (etanercept, infliximab) • Sandoz (adalimumab, etanercept, infliximab) • UCB Pharma (certolizumab pegol)

Consultees	Commentators (no right to submit or appeal)
<u>Others</u> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Bassetlaw CCG • NHS Doncaster CCG • NHS England • Welsh Government 	<u>Relevant research groups</u> <ul style="list-style-type: none"> • Bone Research Society • Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • Orthopaedic Research UK • Pain Relief Foundation <u>Associated Public Health Groups</u> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

¹ Non company consultees are invited to submit statements relevant to the group they are representing.

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.